Artiva Biotherapeutics (ARTV) FDA Approvals $7.99 +0.15 (+1.91%) Closing price 04:00 PM EasternExtended Trading$7.98 0.00 (-0.06%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Artiva Biotherapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Artiva Biotherapeutics (ARTV). Over the past two years, Artiva Biotherapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as AlloNK®. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. AlloNK® + rituximab FDA Regulatory Timeline and Events AlloNK® + rituximab is a drug developed by Artiva Biotherapeutics for the following indication: For the treatment of B-cell driven diseases. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Data Presentation - May 19,2026Data Presentation Drug: AlloNK® + rituximabAnnounced Date: May 19, 2026Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, Inc announced upcoming data presentations at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3 – 6, 2026 in London..AI SummaryArtiva Biotherapeutics said it will present new data at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place June 3 to 6 in London. The company will also host a live webcast on Monday, June 8, 2026, at 8:15 a.m. EDT to review the abstracts and discuss the findings. Members of Artiva’s executive team will be joined by Paul Emery CBE, FLSW, MA, MD, FRCP, FMedSci, a rheumatology professor at the University of Leeds and director of the Leeds NIHR Biomedical Research Centre. The discussion will focus on AlloNK in refractory rheumatoid arthritis and other autoimmune diseases. More details on the abstracts will be available through the EULAR 2026 Congress website. Artiva Biotherapeutics is based in San Diego, California.Read AnnouncementPositive Data - May 8,2026Positive Data Drug: AlloNK® + rituximabAnnounced Date: May 8, 2026Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, Inc. announced positive initial clinical data from ongoing clinical trials evaluating AlloNK® (also known as AB-101) in combination with rituximab.AI SummaryArtiva Biotherapeutics reported positive initial clinical data for AlloNK (AB-101) given with rituximab in autoimmune trials. In a company-sponsored Phase 2a basket trial, refractory rheumatoid arthritis patients showed a 71% ACR50 response at six months of follow-up, with no patients relapsing or needing new immunomodulatory drugs. AlloNK plus rituximab was well tolerated in outpatient community rheumatology settings: no cytokine release syndrome (CRS), no ICANS, and no treatment discontinuations were observed. More than 70 autoimmune patients have been treated with AlloNK across over 40 mostly community sites, supporting a planned registrational trial expected to start in the second half of 2026. Data also showed deep B‑cell depletion and reconstitution consistent with the proposed mechanism, plus early responses in Sjögren disease and systemic sclerosis, suggesting broader potential across B‑cell‑driven autoimmune diseases. A two-dose AlloNK regimen with conditioning and rituximab is being proposed for the next trial.Read Announcementsafety and translational data - November 12,2025Safety And Translational Data Drug: AlloNK® + rituximabAnnounced Date: November 12, 2025Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, Inc. announced positive initial safety and translational data from ongoing clinical trials of AlloNK® (also known as AB-101) in combination with rituximab or obinutuzumab for the treatment of autoimmune disease.AI SummaryArtiva Biotherapeutics reported positive initial safety and translational data for AlloNK (AB-101) given with rituximab or obinutuzumab in autoimmune disease. As of the October 1, 2025 cutoff, 32 patients across diseases including refractory rheumatoid arthritis, Sjögren’s, lupus and systemic sclerosis received outpatient treatment (1 billion or 4 billion cells per dose), mostly at community rheumatology sites. This shows the regimen can be delivered outside hospital oncology units. The treatment was generally well tolerated: most side effects were temporary Grade 1–2 and consistent with the cyclophosphamide/fludarabine conditioning. There were no AlloNK-related Grade 3+ adverse events, no cytokine release syndrome (CRS), no ICANS, no graft-versus-host disease, and no hypogammaglobulinemia. One unrelated hospitalization for skin infection was reported. Translational results showed deep B‑cell depletion: all 23 patients with samples had non‑quantifiable peripheral CD19+ B cells by Day 13, confirmed by a high‑sensitivity assay. Reconstituted B cells in four patients were mainly naïve and transitional. Artiva expects to share initial clinical response data and engage with the FDA on pivotal trial design in the first half of 2026.Read AnnouncementData - May 13,2025Data Phase 1/2Drug: AlloNK® + rituximabAnnounced Date: May 13, 2025Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, I announced new longer-term Phase 1/2 data demonstrating durable responses for AlloNK® (also known as AB-101) in combination with rituximab (RTX) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) at the American Society of Gene & Cell Therapy (ASGCT) 28th annual meeting.ncAI SummaryArtiva Biotherapeutics announced new longer-term Phase 1/2 data at the ASGCT 28th annual meeting demonstrating durable responses using AlloNK® (also called AB-101) combined with rituximab (RTX) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. In this heavily pretreated patient group, which had not received prior CAR-T cell therapy, the combination achieved a 64% complete response rate. The median duration of response has not yet been reached, with data showing it is at least 19.4 months. These impressive results are in line with outcomes seen in approved auto-CAR-T therapies for aggressive B-NHL. The findings support AlloNK’s strong potential to enhance the effectiveness of standard monoclonal antibodies by delivering deep and lasting B-cell depletion, offering hope for improved treatment in challenging cancer and autoimmune disease settings.Read AnnouncementPoster Presentation - April 28,2025Poster Presentation Drug: AlloNK® + rituximabAnnounced Date: April 28, 2025Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, Inc announced that the Company will have a poster presentation on new longer-term Phase 1/2 data for AlloNK® (also known as AB-101) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting taking place May 13-17, 2025, in New Orleans, Louisiana.AI SummaryArtiva Biotherapeutics, Inc. announced that it will present new longer-term Phase 1/2 data on AlloNK® (also known as AB-101) at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, Louisiana, from May 13–17, 2025. The poster presentation (Abstract 858) will share data from patients with relapsed or refractory B-cell non-Hodgkin lymphoma, showing a prolonged response, deep B-cell depletion, and a well-tolerated safety profile for AlloNK® when combined with rituximab. In addition, Artiva will feature another poster (Abstract 1765) that highlights the scalability and consistency of the company’s AlloNK manufacturing process. These sessions aim to demonstrate the potential of AlloNK® as a novel treatment option for challenging B-cell driven diseases, reflecting the company’s commitment to developing effective and accessible cell therapies.Read Announcement Artiva Biotherapeutics FDA Events - Frequently Asked Questions Has Artiva Biotherapeutics received FDA approval? As of now, Artiva Biotherapeutics (ARTV) has not received any FDA approvals for its therapy in the last two years. What drugs has Artiva Biotherapeutics submitted to the FDA? In the past two years, Artiva Biotherapeutics (ARTV) has reported FDA regulatory activity for AlloNK® + rituximab. What is the most recent FDA event for Artiva Biotherapeutics? The most recent FDA-related event for Artiva Biotherapeutics occurred on May 19, 2026, involving AlloNK® + rituximab. The update was categorized as "Data Presentation," with the company reporting: "Artiva Biotherapeutics, Inc announced upcoming data presentations at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3 – 6, 2026 in London.." What conditions do Artiva Biotherapeutics' current drugs treat? Currently, Artiva Biotherapeutics has one therapy (AlloNK® + rituximab) targeting the following condition: For the treatment of B-cell driven diseases. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Adagio Medical FDA EventsBioCardia FDA EventsCognition Therapeutics FDA EventsCorbus Pharmaceuticals FDA EventsPrecision BioSciences FDA EventsHUTCHMED FDA EventsEli Lilly and Company FDA EventsTeleflex FDA EventsBioMarin Pharmaceutical FDA EventsDiaMedica Therapeutics FDA EventsDyne Therapeutics FDA EventsGuardant Health FDA EventsLigand Pharmaceuticals FDA EventsMadrigal Pharmaceuticals FDA EventsMetaVia FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Savara FDA Events Phathom Pharmaceuticals FDA Events Cullinan Therapeutics FDA Events Design Therapeutics FDA Events SELLAS Life Sciences Group FDA Events Schrodinger FDA Events Pharming Group FDA Events Xencor FDA Events Oric Pharmaceuticals FDA Events MeiraGTx FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:ARTV last updated on 5/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Data Presentation - May 19,2026Data Presentation Drug: AlloNK® + rituximabAnnounced Date: May 19, 2026Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, Inc announced upcoming data presentations at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3 – 6, 2026 in London..AI SummaryArtiva Biotherapeutics said it will present new data at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place June 3 to 6 in London. The company will also host a live webcast on Monday, June 8, 2026, at 8:15 a.m. EDT to review the abstracts and discuss the findings. Members of Artiva’s executive team will be joined by Paul Emery CBE, FLSW, MA, MD, FRCP, FMedSci, a rheumatology professor at the University of Leeds and director of the Leeds NIHR Biomedical Research Centre. The discussion will focus on AlloNK in refractory rheumatoid arthritis and other autoimmune diseases. More details on the abstracts will be available through the EULAR 2026 Congress website. Artiva Biotherapeutics is based in San Diego, California.Read Announcement
Positive Data - May 8,2026Positive Data Drug: AlloNK® + rituximabAnnounced Date: May 8, 2026Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, Inc. announced positive initial clinical data from ongoing clinical trials evaluating AlloNK® (also known as AB-101) in combination with rituximab.AI SummaryArtiva Biotherapeutics reported positive initial clinical data for AlloNK (AB-101) given with rituximab in autoimmune trials. In a company-sponsored Phase 2a basket trial, refractory rheumatoid arthritis patients showed a 71% ACR50 response at six months of follow-up, with no patients relapsing or needing new immunomodulatory drugs. AlloNK plus rituximab was well tolerated in outpatient community rheumatology settings: no cytokine release syndrome (CRS), no ICANS, and no treatment discontinuations were observed. More than 70 autoimmune patients have been treated with AlloNK across over 40 mostly community sites, supporting a planned registrational trial expected to start in the second half of 2026. Data also showed deep B‑cell depletion and reconstitution consistent with the proposed mechanism, plus early responses in Sjögren disease and systemic sclerosis, suggesting broader potential across B‑cell‑driven autoimmune diseases. A two-dose AlloNK regimen with conditioning and rituximab is being proposed for the next trial.Read Announcement
safety and translational data - November 12,2025Safety And Translational Data Drug: AlloNK® + rituximabAnnounced Date: November 12, 2025Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, Inc. announced positive initial safety and translational data from ongoing clinical trials of AlloNK® (also known as AB-101) in combination with rituximab or obinutuzumab for the treatment of autoimmune disease.AI SummaryArtiva Biotherapeutics reported positive initial safety and translational data for AlloNK (AB-101) given with rituximab or obinutuzumab in autoimmune disease. As of the October 1, 2025 cutoff, 32 patients across diseases including refractory rheumatoid arthritis, Sjögren’s, lupus and systemic sclerosis received outpatient treatment (1 billion or 4 billion cells per dose), mostly at community rheumatology sites. This shows the regimen can be delivered outside hospital oncology units. The treatment was generally well tolerated: most side effects were temporary Grade 1–2 and consistent with the cyclophosphamide/fludarabine conditioning. There were no AlloNK-related Grade 3+ adverse events, no cytokine release syndrome (CRS), no ICANS, no graft-versus-host disease, and no hypogammaglobulinemia. One unrelated hospitalization for skin infection was reported. Translational results showed deep B‑cell depletion: all 23 patients with samples had non‑quantifiable peripheral CD19+ B cells by Day 13, confirmed by a high‑sensitivity assay. Reconstituted B cells in four patients were mainly naïve and transitional. Artiva expects to share initial clinical response data and engage with the FDA on pivotal trial design in the first half of 2026.Read Announcement
Data - May 13,2025Data Phase 1/2Drug: AlloNK® + rituximabAnnounced Date: May 13, 2025Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, I announced new longer-term Phase 1/2 data demonstrating durable responses for AlloNK® (also known as AB-101) in combination with rituximab (RTX) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) at the American Society of Gene & Cell Therapy (ASGCT) 28th annual meeting.ncAI SummaryArtiva Biotherapeutics announced new longer-term Phase 1/2 data at the ASGCT 28th annual meeting demonstrating durable responses using AlloNK® (also called AB-101) combined with rituximab (RTX) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. In this heavily pretreated patient group, which had not received prior CAR-T cell therapy, the combination achieved a 64% complete response rate. The median duration of response has not yet been reached, with data showing it is at least 19.4 months. These impressive results are in line with outcomes seen in approved auto-CAR-T therapies for aggressive B-NHL. The findings support AlloNK’s strong potential to enhance the effectiveness of standard monoclonal antibodies by delivering deep and lasting B-cell depletion, offering hope for improved treatment in challenging cancer and autoimmune disease settings.Read Announcement
Poster Presentation - April 28,2025Poster Presentation Drug: AlloNK® + rituximabAnnounced Date: April 28, 2025Indication: For the treatment of B-cell driven diseasesAnnouncementArtiva Biotherapeutics, Inc announced that the Company will have a poster presentation on new longer-term Phase 1/2 data for AlloNK® (also known as AB-101) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting taking place May 13-17, 2025, in New Orleans, Louisiana.AI SummaryArtiva Biotherapeutics, Inc. announced that it will present new longer-term Phase 1/2 data on AlloNK® (also known as AB-101) at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, Louisiana, from May 13–17, 2025. The poster presentation (Abstract 858) will share data from patients with relapsed or refractory B-cell non-Hodgkin lymphoma, showing a prolonged response, deep B-cell depletion, and a well-tolerated safety profile for AlloNK® when combined with rituximab. In addition, Artiva will feature another poster (Abstract 1765) that highlights the scalability and consistency of the company’s AlloNK manufacturing process. These sessions aim to demonstrate the potential of AlloNK® as a novel treatment option for challenging B-cell driven diseases, reflecting the company’s commitment to developing effective and accessible cell therapies.Read Announcement
